• WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody.
• InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April 2023.
• WuXi Biologics will leverage its global manufacturing network and dual-sourcing strategy to support InflaRx in making Gohibic available to patients as quickly as possible.

Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic, a first-in-class monoclonal anti-human complement factor C5a antibody.

With a global manufacturing network that includes facilities in the United States, Ireland, Germany, China and Singapore, WuXi Biologics leverages its development and manufacturing technologies to provide more efficient and cost-effective production of drug substances (DS) and drug products (DP), delivering commercial biologics for global clients and enabling promising treatments delivered to patients worldwide.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are proud of this manufacturing partnership with InflaRx for Gohibic. The partnership represents another remarkable milestone in our efforts to establish a robust manufacturing network on a global scale. We are fully committed to leveraging our global network, expertise and experience to make this important new treatment available as rapidly as possible to help improve the lives of many patients."

Prof. Niels C. Riedemann, CEO and Founder of InflaRx, commented, "We are pleased to collaborate with WuXi Biologics as our important manufacturing partner for Gohibic. Together we will now ramp up production under high pressure to roll out supply in order to serve the patient population in need as soon as possible. With its advanced technologies and proven expertise, WuXi Biologics has helped us enormously in our application to the FDA for Gohibic's emergency use authorization. We look forward to continuing this important manufacturing partnership to potentially benefit patients in additional other areas of the world."

About InflaRx

InflaRx GmbH (in Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together "InflaRx").

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a / C5aR technologies to discover and develop first-in-class or best-in-class, potent and specific inhibitors C5a and C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA